ArticleFrontiers in cell and developmental biology2026
Transcriptional regulatory network analysis uncovers modular gene control and potential key regulators in diabetic cardiomyopathy.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic cardiomyopathy (DCM) arises from the interplay of metabolic overload, inflammation, and structural remodeling that ultimately impair cardiac function. However, the transcriptional mechanisms coordinating these pathogenic processes remain incompletely defined. This study aimed to reconstruct and functionally characterize the transcriptional regulatory architecture associated with DCM. Methods: We combined differential expression data from human hiPSC-derived cardiomyocytes exposed to diabetic conditions with literature-curated transcription factor-target interactions to reconstruct a comprehensive transcriptional regulatory subnetwork for DCM. Network topology and functional enrichment analyses were performed to identify regulatory modules and hierarchical organization. Selected network-derived predictions were experimentally evaluated in a type 2 diabetes mouse model. Results: Transcriptional reprogramming was organized into six functional modules encompassing metabolic, inflammatory, hypoxic, fibrotic, and hormonal pathways. Established DCM-associated transcription factors, including FOS, JUN, STAT3, and MYC, ranked among the highest-centrality hubs. Notably, ESR1, a key regulator of estrogen signaling, emerged as a previously unrecognized high-centrality node within the DCM network. In contrast, TRPS1, HBP1, and NFIA showed lower centrality and operated as locally acting regulators, consistent with a multilayered regulatory architecture. Experimental validation in diabetic mice demonstrated significant downregulation of ESR1 and STAT6, together with upregulation of TRPS1 and HBP1, supporting cross-species concordance of selected regulatory signatures. Discussion: These findings define the modular organization of a curated transcriptional regulatory subnetwork underlying DCM and highlight candidate regulators that warrant future functional perturbation studies and biomarker-oriented validation. This integrative network-based framework provides mechanistic insight into transcriptional coordination in diabetic cardiac disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.